Hong Kong Journal of Nephrology
Volume 8, Issue 2 , Pages 61-67, October 2006

Do Captopril Renogram and Losartan Renogram Influence the Choice of Drug (Angiotensin Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker) to be Initiated in Renal Patients?

  • R. Ram

      Affiliations

    • Department of Nephrology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, India
    • Corresponding Author InformationAddress correspondence and reprint requests to: Dr. R. Ram, Department of Nephrology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad 500 082, India. Fax: (+91) 40-23307899
    • ,
  • K.V. Dakshinamurty

      Affiliations

    • Department of Nephrology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, India
    • ,
  • Neela Prasad

      Affiliations

    • Department of Nephrology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, India
    • ,
  • Pushpalatha Sudhakar

      Affiliations

    • Department of Nuclear Medicine, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, India
    • Department of Nephrology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, India

Article Outline

Background

The objectives of this study were to investigate the effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin (AT) II receptor blockers on glomerular filtration rate (GFR) as measured by radionuclide renogram study, and to assess the value of changes in GFR modification with AT-II receptor blocker/ACE inhibitor in determining the drug choice between ACE inhibitors and AT-II receptor blockers. Methods: A total of 14 patients with type 2 diabetes or hypertension were subjected to baseline diethylene triamine pentaacetic acid (DTPA) renogram followed by captopril and losartan renograms. The patients were followed in a prospective randomized controlled crossover trial. Patients were treated with either enalapril or losartan initially for 6 months, followed by the other drug in the later 6 months of the study period. Patients with renal arterial disease, obstructive uropathy, urinary tract infection, acute renal failure or serum creatinine more than 3 mg/dL were excluded from the study.

Results

Our data showed that irrespective of the initial choice of drug, either ACE inhibitor or AT-II receptor blocker, there was an initial fall in GFR (noticed at 3 and 6 months) followed by an increase in GFR at the end of 1 year. But neither the initial fall in GFR nor serum creatinine at the end of 6 months were different. This shows that initial fall in GFR might not be associated with a rise in serum creatinine.

Conclusion

Patients may respond differently after intervention with captopril or losartan as evidenced by radionuclide renogram study. The acute decline in GFR after captopril and losartan may be a pointer to the utility of radionuclide DTPA renogram study in choosing which drug - ACE inhibitor or AT-II receptor blocker - to use in patients requiring them. An acute increase in GFR may not always suggest lack of benefit with that particular drug. This is especially true with AT-II receptor blockers, where the effects of AT2 receptors appear to have an influential role.

Key words:  angiotensin II receptor blocker , captopril renogram , glomerular filtration rate , inhibitor , losartan renogram , radionuclide renogram

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Goldblatt H , Lynch J , Hanzal RF . Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia . J Exp Med . 1934;59:347–379
  2. Brunner HR , Gavras H , Laragh JH . Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure . Lancet . 1973;2:1045–1048
  3. Burnier M , Brunner HR . Angiotensin II receptor antagonists . Lancet . 2000;355:637–645
  4. Arima S , Ito S . Angiotensin II type 2 receptors in the kidney: evidence for endothelial-cell-mediated renal vasodilatation . Nephrol Dial Transplant . 2000;15:448–451
  5. Endo Y , Arima S . Function of angiotensin II type 2 receptors in the post glomerular efferent arteriole . Kidney Int . 1997;52(Suppl 63):S205–S207
  6. Agarwal R . Add-on angiotensin receptor blockade with maximized ACE inhibition . Kidney Int . 2001;59:2282–2289
  7. Mombouli JV . ACE inhibition, endothelial function and coronary artery lesions. Role of kinins and nitric oxide . Drugs . 1997;54(Suppl 50):12–22
  8. Sirgay HM , Carey RM . The subtype 2(AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats . J Clin Invest . 1997;100:264–269
  9. Stergiou GS , Skeva II , Baibas NM , Kalkana CB , Roussias LG , Mountokalakis TD . Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism? . Am J Hypertens . 2001;14(7 Pt 1):688–693
  10. American Diabetes Association  . Clinical Practice Guidelines 2000 . Diabetes Care . 2000;23(Suppl):S1
  11. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program. NIH Publication No. 98-4080, November 1997:p17.
  12. Taylor AT , Fletcher JW , Nally JV , Blaufox MD , Dubovsky EV , Fine EJ , et al.   Procedure guideline for diagnosis of renovascular hypertension. Society of Nuclear Medicine . J Nucl Med . 1998;39:1297–1302
  13. Bakris GL , Weir MR . Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? . Arch Intern Med . 2000;160:685–693
  14. Apperloo AJ , de Zeeuw D , de Jong PE . A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function . Kidney Int . 1997;51:793–797
  15. Ichikawa I . Will angiotensin II receptor antagonists be renoprotective in humans? . Kidney Int . 1996;50:684–692

PII: S1561-5413(09)60234-9

doi:10.1016/S1561-5413(09)60234-9

Hong Kong Journal of Nephrology
Volume 8, Issue 2 , Pages 61-67, October 2006

Article Tools